Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Accelerated Neuromodulation Therapy and Neurocomputational Biomarkers in Individuals at Clinical High Risk for Psychosis

NCT07786714 is registered in ClinicalTrials.gov with Douglas Mental Health University Institute as lead sponsor.

NCT NCT07786714
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07786714 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Accelerated Neuromodulation Therapy and Neurocomputational Biomarkers in Individuals at Clinical High Risk for Psychosis
Lead sponsor
Douglas Mental Health University Institute
Phase
Not applicable
Overall status
Recruiting
Start date
August 31, 2026
Completion date
December 31, 2029
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clinical high risk for psychosis (chr), prodromal symptoms, psychotic disorders